F Beeldens

884 citations
11 papers · 647 · 1 hit paper · h-index 6

Impact in

  • Hematology top 2%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Multiple Myeloma Research and Treatments
  • Genetics top 10%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

F Beeldens

11 papers receiving 638 citations

F Beeldens's Hit Papers

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 2011 · 408 citations
4080+5+10Years since publication100200300400

Peers

F Beeldens
Comparison fields: 5 of 39
  • Hematology 516
  • Genetics 109
  • Public Health, Environmental and Occupational Health 119
  • Molecular Biology 258
  • Oncology 68
Replace Jan Davis with:
Jan Davis United States
Jiří Mayer Czechia
Rainer Krahl Germany
Leandro de Pádua Silva United States
Chun Yew Fong Australia
Maria Cristina Sauerland Germany
Mary‐Frances McMullin United Kingdom
Bortin Mm United States
L. Noens Belgium
Kaoru Nagata Japan
F Beeldens relative to Jan Davis United States Jan Davis's profile →
Citations per field
00.5×1.5×2.3×
Jan Davis · 1×
Citations per year

Countries citing papers authored by F Beeldens

Since Specialization
Citations

This map shows the geographic impact of F Beeldens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F Beeldens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F Beeldens more than expected).

Fields of papers citing papers by F Beeldens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F Beeldens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F Beeldens. The network helps show where F Beeldens may publish in the future.

Co-authors

The 25 scholars most cited alongside F Beeldens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with F Beeldens Line = papers co-authored together F Beeldens links everyone, so they are left out of the graph.

All Works

11 of 11 papers shown
#Work
1
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Hit paper breakdown →
2011408
2
Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups.
200463
3 200563
4 200853
5 200331
6 200617
7 20135
8 20043
9 20082
10
Cytogenetic risk group and cytogenetic response predict outcome of patients with poor-risk mds and secondary aml treated with intensive chemotherapy and stem cell transplantation in a joint study (CRIANT) of the EORTC, EBMT, SAKK, HOVON and GIMEMA leukemia groups
20011
11 20051

About F Beeldens

F Beeldens is a scholar working on Hematology, Public Health, Environmental and Occupational Health, Molecular Biology, Oncology and Organic Chemistry, having authored 11 papers that have together received 647 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (3 papers), Cancer therapeutics and mechanisms (2 papers), Multiple Myeloma Research and Treatments (2 papers), Hematopoietic Stem Cell Transplantation (2 papers), Chronic Myeloid Leukemia Treatments (1 paper), Head and Neck Cancer Studies (1 paper) and Synthesis and Biological Evaluation (1 paper). The work is most often cited by research in Hematology (516 citations), Genetics (109 citations), Public Health, Environmental and Occupational Health (119 citations), Molecular Biology (258 citations) and Oncology (68 citations). F Beeldens has collaborated with scholars based in Belgium, Italy and Netherlands. Frequent co-authors include Petra Muus, Stefan Suciu, Dominik Selleslag, Liliana Baila, Boris Labar, Helmut R. Salih, Théo de Witte, Pierre W. Wijermans, Michael Lübbert and Aristoteles Giagounidis. Their work appears in journals such as Blood, Leukemia, Journal of Clinical Oncology, Leukemia Research and Journal of Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact